Teligent Total Liabilities 2012-2021 | TLGT
Teligent total liabilities from 2012 to 2021. Total liabilities can be defined as the total value of all possible claims against the corporation.
|
Teligent Annual Total Liabilities (Millions of US $) |
|
|---|---|
| 2020 | $198 |
| 2019 | $212 |
| 2018 | $172 |
| 2017 | $140 |
| 2016 | $127 |
| 2015 | $114 |
| 2014 | $158 |
| 2013 | $8 |
| 2012 | $3 |
| 2011 | $2 |
|
Teligent Quarterly Total Liabilities (Millions of US $) |
|
|---|---|
| 2021-06-30 | $134 |
| 2021-03-31 | $133 |
| 2020-12-31 | $198 |
| 2020-09-30 | $230 |
| 2020-06-30 | $228 |
| 2020-03-31 | $219 |
| 2019-12-31 | $212 |
| 2019-09-30 | $196 |
| 2019-06-30 | $188 |
| 2019-03-31 | $182 |
| 2018-12-31 | $172 |
| 2018-09-30 | $157 |
| 2018-06-30 | $148 |
| 2018-03-31 | $141 |
| 2017-12-31 | $140 |
| 2017-09-30 | $144 |
| 2017-06-30 | $138 |
| 2017-03-31 | $132 |
| 2016-12-31 | $127 |
| 2016-09-30 | $125 |
| 2016-06-30 | $124 |
| 2016-03-31 | $122 |
| 2015-12-31 | $114 |
| 2015-09-30 | $115 |
| 2015-06-30 | $120 |
| 2015-03-31 | $153 |
| 2014-12-31 | $158 |
| 2014-09-30 | $15 |
| 2014-06-30 | $8 |
| 2014-03-31 | $7 |
| 2013-12-31 | $8 |
| 2013-09-30 | $6 |
| 2013-06-30 | $5 |
| 2013-03-31 | $4 |
| 2012-12-31 | $3 |
| 2012-09-30 | $2 |
| 2012-06-30 | $2 |
| 2012-03-31 | $2 |
| 2011-12-31 | $2 |
| 2011-09-30 | $2 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.000B | $0.000B |
| Teligent, Inc. is a specialty generic pharmaceutical company, develops, manufactures and markets topical formulations primarily in the United States. It sells generic pharmaceutical products in topical, injectable, complex and ophthalmic dosage forms. Teligent Inc., formerly known as IGI Laboratories, Inc., is based in Buena, New Jersey. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |